Atsena Therapeutics
Biotechnology, 5 Laboratory Dr, Durham, North Carolina, 27709, United States, 11-50 Employees
Phone Number: 19*********
Who is ATSENA THERAPEUTICS
Atsena Therapeutics is a clinical-stage gene therapy company developing novel treatments for inherited forms of blindness. The company has two clinical-stage programs, ATSN-201 for X-link...
Read More
-
Headquarters: 5 Laboratory Dr, Durham, North Carolina, 27709, United States
-
Date Founded: 2019
-
Employees: 11-50
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2836
|
NAICS Code: 541714 |
Show More
Does something look wrong? Fix it. | View contact records from ATSENA THERAPEUTICS
Atsena Therapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Atsena Therapeutics
Answer: Atsena Therapeutics's headquarters are located at 5 Laboratory Dr, Durham, North Carolina, 27709, United States
Answer: Atsena Therapeutics's phone number is 19*********
Answer: Atsena Therapeutics's official website is https://atsenatx.com
Answer: Atsena Therapeutics's revenue is $1 Million to $5 Million
Answer: Atsena Therapeutics's SIC: 2836
Answer: Atsena Therapeutics's NAICS: 541714
Answer: Atsena Therapeutics has 11-50 employees
Answer: Atsena Therapeutics is in Biotechnology
Answer: Atsena Therapeutics contact info: Phone number: 19********* Website: https://atsenatx.com
Answer: Atsena Therapeutics is a clinical-stage gene therapy company developing novel treatments for inherited forms of blindness. The company has two clinical-stage programs, ATSN-201 for X-linked retinoschisis (XLRS) and ATSN-101 for GUCY2D-associated Leber congenital amaurosis (LCA1). ATSN-201, which leverages the companys novel spreading capsid AAV.SPR, is being evaluated in XLRS patients in a Phase I/II clinical trial known as the LIGHTHOUSE study. The companys additional proprietary asset is ATSN-301, a dual AAV vector-based gene therapy to prevent blindness from MYO7A-associated Usher syndrome (USH1B). Interim safety and efficacy data from the companys ongoing Phase I/II clinical trial in patients with LCA1 have demonstrated ATSN-101 is well tolerated and clinically meaningful improvements in vision were observed 12 months post-treatment. Founded by ocular gene therapy pioneers Dr. Shannon Boye and Sanford Boye of the University of Florida, Atsena is based in North Carolinas Research Triangle, an environment rich in gene therapy expertise.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month